Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • The Michael J Fox Foundation

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

    The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

    - PMLiVE

    Sanofi’s investigational frexalimab shows promise in relapsing MS study

    Approximately 2.9 million people worldwide are affected by the neurological disease

    - PMLiVE

    Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

    The neurodegenerative condition currently affects nearly ten million people worldwide

    - PMLiVE

    Roche and Ascidian enter neurological disease partnership worth over $1.8bn

    More than three billion people worldwide were living with a neurological condition in 2021

    - PMLiVE

    Tiziana shares promising results for intranasal foralumab in secondary progressive MS

    The neurological disease is estimated to affect 2.8 million people globally

    - PMLiVE

    Tiziana shares promising results for intranasal foralumab in multiple sclerosis

    The neurological disease affects approximately 2.8 million people worldwide

    - PMLiVE

    Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

    The progressive neurodegenerative disease affects seven million people worldwide

    - PMLiVE

    Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

    According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

    - PMLiVE

    Two UK clinical trials launched to identify blood tests for dementia diagnosis

    The neurodegenerative condition affects more than 944,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links